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Simple Summary: Preeclampsia is a life-threatening disorder that occurs in 10% of pregnant women
worldwide. It presents as high blood pressure and multi-organ damage that when left untreated can
result in death to both mother and baby. Treatment involves delivery of the placenta as well as the baby,
often prematurely. Unfortunately, the cause of preeclampsia is unknown. However, there are known
risk factors in women that may contribute to preeclampsia, including obesity. Increased adipose
tissue (fat) has the potential to promote inflammation during pregnancy, which may negatively
impact development of the baby and placenta, and lead to preeclampsia. This study aimed to show
that reversal of maternal obesity through diet lowers inflammation in the fat and improves placental
development, both of which have been shown to be necessary for pregnancy success. Utilizing obese
female mice that demonstrate signs of preeclampsia (BPH/5), we showed that calorie restriction
lowered inflammatory immune factors (complement) in the fat and restored essential growth factors
in the developing placenta. In conclusion, these data suggest that targeting maternal obesity using
calorie restriction and weight loss may improve pregnancy outcomes. Further studies are necessary
to determine the influence of fat reduction in women and their likelihood of developing preeclampsia.
Abstract: Preeclampsia (PE) is a serious hypertensive disorder of pregnancy characterized by
abnormal placental development with an unknown etiology. To better understand which women will
develop PE, a number of maternal risk factors have been identified, including obesity. Visceral white
adipose tissue (WAT) contains inflammatory mediators that may contribute to PE. To explore this,
we utilized the blood pressure high (BPH)/5 mouse model of superimposed PE that spontaneously
recapitulates the maternal PE syndrome. We hypothesized that BPH/5 visceral WAT adjacent to the
female reproductive tract (reproductive WAT) is a source of complement factors that contribute to
the inflammatory milieu and angiogenic imbalance at the maternal–fetal interface in this model and
in preeclamptic women. To test our hypothesis, we calorie-restricted BPH/5 females for two weeks
prior to pregnancy and the first seven days of pregnancy, which attenuated complement component 3
(C3) but not complement factor B, nor complement factor D, (adipsin) in the reproductive WAT or
the implantation site in BPH/5. Furthermore, calorie restriction during pregnancy restored vascular
endothelial and placental growth factor mRNA levels in the BPH/5 implantation site. These data show
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maternal reproductive WAT may be a source of increased C3 during pregnancy, which is increased at
the maternal–fetal interface in preeclamptic BPH/5 mice. It also suggests that calorie restriction could
regulate inflammatory mediators thought to contribute to placental dysfunction in PE. Future studies
are necessary to examine the effect of calorie restriction on C3 throughout pregnancy and the role of
maternal obesity in PE.
Keywords: preeclampsia; placenta; complement; obesity; adiposity

1. Introduction
Approximately one in every three women of reproductive age (15–49 years) in the US has obesity;
a risk factor for multiple adverse pregnancy outcomes, including gestational diabetes, hypertension,
macrosomia, and preeclampsia (PE) [1] PE is a serious disorder of pregnancy characterized by high
blood pressure and multiorgan dysfunction during the second half of gestation [2–4]. Although the
etiology remains unknown, delivery of both the baby and placenta is often necessary to prevent fetal
and maternal morbidity and mortality [1]. Therefore, the placenta is thought to play a causal role in
PE [2].
Successful placental development depends on several tightly regulated physiological processes,
including implantation, decidualization, and angiogenesis [2]. PE is associated with inadequate
trophoblast invasion and remodeling of spiral arteries as a result of angiogenic, immune,
and inflammatory dysregulation at the maternal–fetal interface [3,5]. Vascular endothelial growth factor
(VEGF) and placental growth factor (PlGF) are necessary for placental vasculature development and are
dysregulated in PE [6]. This, along with increased activation of the complement system, is associated
with a systemic and placental angiogenic imbalance in preeclamptic women and rodent models of
PE [7]. Furthermore, the complement system was previously indicated to be a key regulator of the
maternal immune response during pregnancy. Failure of the complement system to properly mediate
the clearance of waste and debris created during placentation may contribute to the pathogenesis of
PE [8].
The complement system can be activated both systemically and locally through three distinct,
well-described pathways, namely, classical, lectin, and alternative [3,9,10]. C3 (Complement
component 3), a protein that plays a major role in the complement system, is the converging point
of all three pathways, with the classical and alternative pathways mechanisms of great interest in
PE. Both CfB (Complement factor B) and adipsin (Complement factor D), which are involved in
the alternative complement pathway, contribute to the production of C3 [4,9]. Increased circulating
C3a, a product of the proteolytic cleavage of C3, combined with obesity was associated with a
high incidence of PE [4]. Regulation of C3 was demonstrated to be critical in ensuring a healthy
pregnancy [8]. Furthermore, adipsin was suggested as a potential biomarker for susceptibility of PE in
early pregnancy [11]. These observed increases in levels of circulating complement factors associated
with PE and their link to obesity warrant further investigation.
Adipose tissue is a source of adipokines, cytokines, and complement proteins that, when activated,
contribute to obesity-driven systemic inflammation [12]. It was proposed that visceral adipose tissue
located adjacent to the developing placenta may influence angiogenic signaling at the maternal–fetal
interface [3]. To investigate this phenomenon, we utilized the preeclamptic-like blood pressure
high (BPH)/5 mouse model [2,13], which is used for studying pre-pregnancy and early pregnancy
events that may contribute to PE, as BPH/5 spontaneously develops the cardinal maternal signs (late
gestational hypertension and proteinuria) beginning at day 14 of pregnancy, which resolve upon
delivery of pups and placentae [2,13]. BPH/5 females are hyperphagic and subsequently show increased
adiposity, including increased reproductive visceral white adipose tissue (WAT) deposition adjacent
to the reproductive tract before and during pregnancy [14]. Recently, Sones et al. demonstrated
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that expression of VEGF and PlGF, as well as CfB and C3, are upregulated at the maternal–fetal
interface of BPH/5 mice at the peak of decidualization in murine pregnancy at embryonic day (e)
7.5 [7]. However, expression of complement C1q subcomponent subunit A (C1qa) was similar in
BPH/5 and controls. Importantly, complement reduction by C3 convertase inhibition rescued BPH/5
pregnancies and was shown to improve fetoplacental development, including spiral artery remodeling
and angiogenic imbalances in the placenta [15]. Furthermore, neutrophil infiltration and tumor
necrosis factor (TNF)-α are also upregulated at the maternal–fetal interface in BPH/5 during early
pregnancy, suggesting complement activation [15]. Additionally, DBA/2-mated CBA/J pregnancies
demonstrate key features of PE including angiogenic dysfunction, proteinuria, and renal injury [16].
Complement inhibition during these pregnancies also showed improvements in maternal proteinuria
and renal dysfunction [16]. This physiological evidence of complement regulation during early
pregnancy in a model of superimposed PE supports further mechanistic investigations. We therefore
hypothesize that reproductive WAT in female BPH/5 mice before and during pregnancy is a source of
complement factors that contribute to the angiogenic imbalance at the maternal–fetal interface and
that calorie restriction (CR) via pair feeding will attenuate this imbalance.
2. Materials and Methods
2.1. Animals
Virgin 8–12 week BPH/5 mice and control C57 (C57BL/6J) mice were used from in-house colonies
maintained at the LSU School of Veterinary Medicine for all experiments. Mice were exposed to a
standard 12 h light/dark cycle. Throughout all experiments, mice were fed ad libitum standard 5001
chow. Pair-feeding of nonpregnant BPH/5 female mice was done as previously described [17] by
feeding the same amount of normal chow to BPH/5 as consumed by age-matched C57 female mice for
2 weeks. Intrastrain timed matings with day of vaginal plug detection denoted as e0.5 were performed
with BPH/5 pair-feeding, beginning at e0.5 and continuing for 7 days until the mice were sacrificed,
as previously described [14]. Reproductive WAT and implantation sites (uterus and embryo) were
collected and flash frozen from ad libitum-fed and pair-fed, nonpregnant and pregnant BPH/5 and C57
female mice. Litter size and pregnancy rates were not significantly altered in BPH/5 mice at e7.5 after
CR (Figure S1). All animal procedures were reviewed and approved by Louisiana State University
(LSU) Institutional Animal Care and Use Committee. Mouse studies met the standards set forth
by the National Institutes of Health (NIH) guidelines on the care and use of animals, United States
Department of Agriculture (USDA) regulations, and the American Veterinary Medical Association
Panel on Euthanasia.
2.2. Gene Expression Analysis
Total RNA was isolated from reproductive WAT of BPH/5 and C57 mice prior to pregnancy, as well
as reproductive WAT and implantation sites at e7.5. Tissue homogenization and cDNA synthesis were
performed as previously described [14]. qRT-PCR was used to determine the amount of C3 (region
corresponding to the alpha chain), CfB, adipsin, VEGF, and PlGF mRNA (Table S1), with 25 ng cDNA
per reaction in triplicate using SYBR green. Relative expression was quantified and expressed as fold
change relative to 18s rRNA using the 2ˆ-delta Ct method, as previously described [14].
2.3. Protein Analysis
Protein lysates were made from e7.5 reproductive WAT samples by homogenizing samples in
RIPA buffer with proteinase inhibitor and quantifying using the Bradford assay. A total of 40 ng
of protein was loaded and separated using 4–12% Bis–Tris Protein Gel (ThermoFisher NP0321,
Waltham, MA, USA) under reducing conditions, then transferred onto a nitrocellulose membrane
blocked in 5% w/v nonfat dry milk/phospahe buffered saline tween (PBST). Complement C3 polyclonal
(rabbit) primary antibody (1:2500) was used to detect C3 α and β bands (ThermoFisher PA5-21349,
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Waltham,
USA) with goat anti-rabbit horseradish peroxidase (HRP)-conjugated secondary
antibody (Jackson Immunoresearch 11-035-003, West Grove, PA, USA) and mouse anti-actin primary
conjugated
secondary
antibody
Biotechnologies,
Dallas, TX,
USA) (Figuresecondary
S3). Band
antibody
(1:5000,
Sigma Aldrich,
St.(Santa
Louis, Cruz
MO, USA)
with goat-anti-mouse
HRP-conjugated
intensity
was
measured
and
normalized
to
actin
with
ImageJ
software
(NIH,
Bethesda,
MD,
antibody (Santa Cruz Biotechnologies, Dallas, TX, USA) (Figure S3). Band intensity was measuredUSA)
and
following previously
published
methods(NIH,
[2]. Bethesda, MD, USA) following previously published
normalized
to actin with
ImageJ software
methods [2].
2.4. Statistical Analysis
2.4. Statistical Analysis
Statistical analyses were performed using GraphPad Prism, Version 8.0. Data were presented as
mean
± standard
error were
of theperformed
mean (SEM).
qRT-PCR
were
analyzed
with
t-test
orwere
one-way
ANOVA
Statistical
analyses
using
GraphPad
Prism,
Version
8.0.
Data
presented
as
followed
by Tukey
comparisons.
Westernwere
blot analyzed
quantifications
wereoranalyzed
onemean
± standard
errorpost-hoc
of the mean
(SEM). qRT-PCR
with t-test
one-way with
ANOVA
tailed tbytests
BPH/5.comparisons.
Assumptions
of these
models (linearity,
normality
residuals,
followed
Tukeytopost-hoc
Western
blot quantifications
were analyzed
withofone-tailed
t
homoscedasticity
of
residuals)
and
influential
data
points
were
assessed
by
examining
standardized
tests to BPH/5. Assumptions of these models (linearity, normality of residuals, homoscedasticity of
residual and
plots,
the normality
of residual
was confirmed
using residual
the Shapiro–Wilk
test.
residuals)
andquantile
influential
dataand
points
were assessed
by examining
standardized
and quantile
Statistical
significance
definedwas
as pconfirmed
< 0.05. using the Shapiro–Wilk test. Statistical significance
plots,
and the
normality was
of residual
was defined as p < 0.05.
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3. Results
3.1. Complement Factor 3 mRNA is Upregulated in the Reproductive WAT of BPH/5 Females Prior to
3.1.
Complement Factor 3 mRNA is Upregulated in the Reproductive WAT of BPH/5 Females Prior to
Pregnancy
Pregnancy
We previously showed that CR via pair feeding not only reduces body weight and visceral WAT
We previously showed that CR via pair feeding not only reduces body weight and visceral
mass, but also lowers TNFα and interleukin (IL)-6 mRNA in BPH/5 female reproductive WAT [17].
WAT mass, but also lowers TNFα and interleukin (IL)-6 mRNA in BPH/5 female reproductive
Although complement dysregulation was demonstrated as early as e5.5 in BPH/5 pregnancy, a preWAT [17]. Although complement dysregulation was demonstrated as early as e5.5 in BPH/5 pregnancy,
pregnancy contribution is not yet clear. Thus, we sought to determine whether known obesity-related
a pre-pregnancy contribution is not yet clear. Thus, we sought to determine whether known
complement factors were upregulated in BPH/5 reproductive WAT and could be attenuated through
obesity-related complement factors were upregulated in BPH/5 reproductive WAT and could be
restricting caloric intake for two weeks prior to pregnancy. We hypothesized that pre-existing
attenuated through restricting caloric intake for two weeks prior to pregnancy. We hypothesized
maternal obesity is a source of increased complement in the BPH/5 mouse model. We measured key
that pre-existing maternal obesity is a source of increased complement in the BPH/5 mouse model.
complement components and factors (CfB, adipsin, and C3) by qRT-PCR in the visceral reproductive
We measured key complement components and factors (CfB, adipsin, and C3) by qRT-PCR in the visceral
WAT of ad libitum-fed, nonpregnant C57 and BPH/5 female mice. Although adipsin mRNA levels
reproductive WAT of ad libitum-fed, nonpregnant C57 and BPH/5 female mice. Although adipsin
were not significantly different in the reproductive WAT between ad libitum-fed, nonpregnant C57
mRNA levels were not significantly different in the reproductive WAT between ad libitum-fed,
and BPH/5 females (Figure 1B), CfB and C3 mRNA were both elevated as well as reduced after CR
nonpregnant C57 and BPH/5 females (Figure 1B), CfB and C3 mRNA were both elevated as well as
(Figure 1A,C). This CR paradigm was effective in reducing C3 and CfB mRNA in BPH/5 reproductive
reduced after CR (Figure 1A,C). This CR paradigm was effective in reducing C3 and CfB mRNA in
WAT.
BPH/5 reproductive WAT.

(A)

(B)

(C)

Figure
Figure1.1.Complement
Complementfactor
factorBB(CfB)
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Be Attenuated
Reducing Adiposity
Caloriebyrestriction
(CR) via pair-feeding BPH/5 female mice at conception was shown to lower
body
weight,
adiposity,
circulating
leptin
bymice
e7.5
[14]. Furthermore,
attenuated
Calorie
restriction
(CR) viaand
pair-feeding
BPH/5
female
at conception
was shown CR
to lower
body
proinflammatory
markers
in
the
reproductive
WAT
and
implantation
sites
at
e7.5
in
BPH/5
[14]. To
weight, adiposity, and circulating leptin by e7.5 [14]. Furthermore, CR attenuated proinflammatory
better inunderstand
the adipose-dependent
inflammatory
in BPH/5
observed
in the
early
markers
the reproductive
WAT and implantation
sites at e7.5 inprofile
BPH/5 [14].
To better
understand
pregnancy
[14],
we
measured
CfB,
adipsin,
and
C3
mRNA
in
the
reproductive
WAT
at
e7.5
in
adipose-dependent inflammatory profile in BPH/5 observed in early pregnancy [14], we measured CfB,ad
libitum-fed
and BPH/5
females as well
asatBPH/5
that were
calorie
restricted
via pairadipsin,
and C3C57
mRNA
in the reproductive
WAT
e7.5 infemales
ad libitum-fed
C57
and BPH/5
females
as
feeding
for
the
first
seven
days
of
pregnancy.
While
complement
mRNA
expression
was
not
different
well as BPH/5 females that were calorie restricted via pair-feeding for the first seven days of pregnancy.
between
C57 andmRNA
BPH/5expression
pregnant was
reproductive
WAT
(Figure
VEGF
mRNAreproductive
increased 10While
complement
not different
between
C57S2A–C),
and BPH/5
pregnant
fold
in
BPH/5
e7.5
reproductive
WAT,
which
was
attenuated
by
seven
days
of
CR
in
BPH/5
WAT (Figure S2A–C), VEGF mRNA increased 10-fold in BPH/5 e7.5 reproductive WAT, whichfemales
was
(Figure
S2D).
attenuated by seven days of CR in BPH/5 females (Figure S2D).
Amelioration
several
adverse
pregnancy
outcomesinin
BPH/5
occurred
after
convertase
Amelioration
ofof
several
adverse
pregnancy
outcomes
BPH/5
occurred
after
C3C3
convertase
inhibition
[15],
which
decreases
complement
components
downstream
CfB
and
adipsin,
including
inhibition
[15],
which
decreases
complement
components
downstream
of of
CfB
and
adipsin,
including
C3
[18].
Therefore,
further
analysis
of
C3
was
performed
to
better
understand
its
expression
BPH/5
C3 [18]. Therefore, further analysis of C3 was performed to better understand its expression inin
BPH/5
pregnancy,
specifically
C3
protein
in
the
reproductive
WAT
at
e7.5.
C3
is
cleaved
to
produce
the
two
pregnancy, specifically C3 protein in the reproductive WAT at e7.5. C3 is cleaved to produce the two
fragments
C3a
and
C3b,
while
constituent
polypeptide
chains
that constitute
the
C3 protein
fragments
C3a
and
C3b,
while
the the
constituent
polypeptide
chains
that constitute
the C3
protein
are theare
the
α
and
β
chains
[19].
Of
note,
the
C3
α
and
β
chains
are
linked
by
disulfide
bonds,
which
α and β chains [19]. Of note, the C3 α and β chains are linked by disulfide bonds, which are reducedare
reduced
under
Western
blotting conditions
and appear
therefore
asbands
separate
bands2D)
(Figure
[20].
under
Western
blotting
conditions
and therefore
as appear
separate
(Figure
[20]. 2D)
It was
It was observed
α total
chainC3and
totalβC3
(α and
β chains
combined)
protein
levels were
observed
that C3 α that
chainC3
and
(α and
chains
combined)
protein
levels were
significantly
significantly
increased
in
the
reproductive
WAT
of
BPH/5
females
compared
to
ad
libitum-fed
C57
increased in the reproductive WAT of BPH/5 females compared to ad libitum-fed C57 females at e7.5
females
at
e7.5
(Figure
2A,C).
BPH/5
females
began
CR
at
e0.5
to
reduce
adiposity,
and
both
C3
(Figure 2A,C). BPH/5 females began CR at e0.5 to reduce adiposity, and both C3 α chain and total C3 α
chain
andsignificantly
total C3 levels
wereinsignificantly
reproductive
WAT
at e7.5 (Figure
2A,C).
levels
were
reduced
reproductivereduced
WAT atin
e7.5
(Figure 2A,C).
Individually
measured,
Individually
measured,
C3
β
chain
protein
levels
were
not
significantly
changed
in
BPH/5
C3 β chain protein levels were not significantly changed in BPH/5 reproductive WAT at e7.5 after CR
at 2B).
e7.5 after CR (p = 0.09, n = 3) (Figure 2B).
(p reproductive
= 0.09, n = 3) WAT
(Figure

Figure 2. Complement factor 3 (C3) protein is increased in BPH/5 reproductive (repro) WAT in early
pregnancy. (A) Quantification of C3 α chain, (B) C3 β chain, and (C) combined (α chain and β
Figure 2. Complement factor 3 (C3) protein is increased in BPH/5 reproductive (repro) WAT in early
chain) C3 levels were measured in reproductive WAT of ad libitum-fed C57, ad libitum-fed BPH/5,
pregnancy. (A) Quantification of C3 α chain, (B) C3 β chain, and (C) combined (α chain and β chain)
and calorie-restricted (CR) BPH/5 mice at e7.5 (n = 3, * p < 0.05 vs. C57, # p < 0.05 vs. BPH/5). Data are
C3 levels were measured in reproductive WAT of ad libitum-fed C57, ad libitum-fed BPH/5, and
expressed as mean ± SEM. (D) Representative Western blot gel of actin and# C3 denatured protein levels.
calorie-restricted (CR) BPH/5 mice at e7.5 (n = 3, * p < 0.05 vs. C57, p < 0.05 vs. BPH/5). Data are
expressed as mean ± SEM. (D) Representative Western blot gel of actin and C3 denatured protein
levels.
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3.3. A Reduction in BPH/5 Maternal Adiposity Lowers C3 and Restores Angiogenic Balance at the
An angiogenic
imbalance
in early
pregnancySites
characterizes BPH/5 mice and other models of PE [1,7].
Maternal–Fetal
Interface
in e7.5 BPH/5
Implantation
Complement inhibition was shown to restore placental VEGF levels in BPH/5 placenta [15]. To further
An angiogenic imbalance in early pregnancy characterizes BPH/5 mice and other models of PE [1,7].
investigate this, we sought to test whether complement reduction via CR improves angiogenic
Complement inhibition was shown to restore placental VEGF levels in BPH/5 placenta [15]. To further
dysregulation in early BPH/5 pregnancy. We measured CfB and C3, as well as VEGF and PlGF, mRNA
investigate this, we sought to test whether complement reduction via CR improves angiogenic
expression in e7.5 implantation sites. Consistent with previous findings [7], both complement (CfB
dysregulation in early BPH/5 pregnancy. We measured CfB and C3, as well as VEGF and PlGF,
and C3) and angiogenic factors (VEFG and PlGF) were upregulated in ad libitum-fed BPH/5 at e7.5
mRNA expression in e7.5 implantation sites. Consistent with previous findings [7], both complement
compared to ad libitum-fed C57 females (Figure 3A–D). C3, VEGF and PlGF were significantly
(CfB and C3) and angiogenic factors (VEFG and PlGF) were upregulated in ad libitum-fed BPH/5 at e7.5
reduced (Figure 3B–D) in BPH/5 CR females. However, CfB was unchanged in BPH/5 CR e7.5
compared to ad libitum-fed C57 females (Figure 3A–D). C3, VEGF and PlGF were significantly reduced
implantation sites (Figure 3A).
(Figure 3B–D) in BPH/5 CR females. However, CfB was unchanged in BPH/5 CR e7.5 implantation
sites (Figure 3A).

A

B

C

D

Figure 3. Complement factor 3 (C3), complement factor B (CfB), vascular endothelial growth factor
(VEGF), and placental growth factor (PlGF) mRNA levels are increased in BPH/5 implantation sites
3. Complement
factor 3 (C3),
complement
factor Bfactor
(CfB), B,
vascular
endothelialcomponent
growth factor
in Figure
early pregnancy.
(A) qRT-PCR
analysis
of complement
(B) complement
3
(VEGF),
and placental
growth
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(PlGF)
mRNAand
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in BPH/5
sites
(C3),
(C) vascular
endothelial
growth
(VEGF),
(D)are
placental
growth
factorimplantation
(PlGF) mRNA
in early pregnancy.
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analysis
oflibitum-fed
complement
factor
(B) complement
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3 (C3),
expression
in implantation
sites from
e7.5 ad
C57
andB,BPH/5,
and calorie-restricted
# p <(VEGF),
(C) vascular
growth
factor
(D) Data
placental
growth factor
(PlGF)
mRNA
BPH/5
mice (n =endothelial
5–6, * p < 0.05
vs. C57,
0.05 vs. and
BPH/5).
are expressed
as mean
± SEM.
expression in implantation sites from e7.5 ad libitum-fed C57 and BPH/5, and calorie-restricted (CR)
4. Discussion
BPH/5 mice (n = 5–6, * p < 0.05 vs. C57, # p < 0.05 vs. BPH/5). Data are expressed as mean ± SEM.

Maternal obesity with excessive visceral adipose tissue, which is rich in proinflammatory
4. Discussion
adipokines
and complement proteins, may impair placentation and contribute to the development of
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Our results showed that C3 and CfB, but not adipsin, were increased in the reproductive WAT of
nonpregnant BPH/5 females compared to controls, indicating that the reproductive WAT may be a
source of complement components, but not necessarily exclusively those involved in the alternative
complement pathway in the BPH/5 model. Pair-feeding was successful in reducing the expression of
C3 and CfB in the reproductive WAT of nonpregnant BPH/5 females, suggesting that reducing adiposity
could be advantageous in correcting a dysregulated inflammatory reproductive WAT milieu prior to
pregnancy. Furthermore, since maternal obesity is thought to contribute to the development of PE,
we hypothesized that this dysregulation would continue into early pregnancy in BPH/5. As expected,
C3 was increased in the reproductive WAT of BPH/5 females at e7.5, when TNF-α mRNA is also
increased in BPH/5 reproductive WAT [14]. BPH/5 females, which were calorie restricted over the
first seven days of pregnancy, presented significantly attenuated C3 levels in the reproductive WAT.
As previously described, 25% CR over the first seven days of pregnancy is not thought to cause maternal
undernutrition, and the amount of reproductive WAT in BPH/5 females by e7.5 is indeed significantly
reduced [14]. Interestingly, CR did not reduce TNF-α in BPH/5 reproductive WAT, but it did attenuate
IL-6 [14]. This finding supported the idea that complement fragment 5a, which promotes the production
of TNF-α [21], may not be activated in early BPH/5 pregnancy. The development of PE in human
women was demonstrated to be associated with increased levels of C3 effector molecules, including
C3a and other complement activation fragments in early gestation [4]. Therefore, further investigations
are warranted in the BPH/5 model.
Complement activity is thought to contribute to PE by promoting an angiogenic imbalance
localized at the maternal–fetal interface [3,22]. Our qRT-PCR data confirmed previously published
RNA-Seq data, demonstrating that C3 and CfB expression are upregulated in BPH/5 implantation
sites at e7.5 [7]. The early pregnancy timepoint studied herein (e7.5) represents peak decidualization
in mice, an important event for successful pregnancy. Thus, dysregulation during this important
time could contribute to placental injury and later manifestation of PE. This study demonstrated that
increased C3 expression at the maternal–fetal interface was significantly attenuated in response to CR
at this timepoint, although CfB was not. This discrepancy in CfB reduction in BPH/5 nonpregnant
reproductive WAT, but not the e7.5 implantation site, may be due to the difference in CR timing with
14 days and 7 days imposed, respectively. Importantly, pregnancy rates and litter sizes at e7.5 were
unchanged by CR in BPH/5 dams. This demonstrated that reduction of C3 did not have an adverse
effect on early pregnancy events, such as fertilization and implantation rates, which was demonstrated
in C3-deficient mice [23]. Furthermore, previously described VEGF and PlGF upregulation in BPH/5
e7.5 implantation sites confirmed the presence of an angiogenic imbalance during early pregnancy [7].
Overexpression of decidual VEGF was shown to promote elevations in the antiangiogenic factor
soluble fms-like tyrosine kinase-1 (sFLT1) while producing a PE-like phenotype in a rodent model [24].
Hypoxia promotes increased expression of VEGF family members at the maternal–fetal interface [25];
therefore, it is interesting that the reproductive WAT adjacent to the implantation site at e7.5 in BPH/5
also showed increased VEGF mRNA. This finding is being further explored to determine individual
cell expression patterns in the WAT fractions, i.e., stromal vascular cells, immune cells, and adipocytes,
in this model and how they may impact local and systemic inflammation and angiogenic levels.
Prior research in BPH/5 mice showed that normalizing the expression of angiogenic factors at
the maternal–fetal interface via the anti-inflammatory drug celecoxib was insufficient to correct the
dysregulated complement expression observed [25]. This makes it especially notable that CR in early
BPH/5 pregnancy attenuated C3 expression at the maternal–fetal interface, as well as restored VEGF
and PlGF expression levels to that of control mice. Although seven days of CR reduced IL-6 mRNA
in the BPH/5 e7.5 implantation site, it failed to alter TNF-α levels [14], suggesting that CR before
pregnancy and continuing into early pregnancy would be more effective than CR initiated at the time
of conception. The CR-induced maternal weight reduction further suggests that adipose tissue and,
specifically, visceral depots may contribute to the inflammatory profile and concomitant placental
angiogenic imbalances seen in PE. The relationship between the complement system and angiogenic
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dysregulation at the maternal–fetal interface was previously linked to immune cells, particularly
macrophages [3]. It was suggested that proteins of the complement system polarize macrophages to
produce antiangiogenic factors, thereby contributing to angiogenic imbalance [21]. Further research
beyond the scope of this brief study is necessary to elucidate this relationship.
This study has some limitations. Calorie restriction during pregnancy is well described as a
developmental origin of disease [26]. However, the paradigm of pair-feeding used in this study
previously normalized body weight and adiposity prior to pregnancy in BPH/5 adult females; therefore,
we do not think that this would cause undernutrition in the experimental conditions [17]. Additionally,
the implementation of a 30% calorie restriction in pregnant women with obesity, intended to minimize
gestational weight gain, was not reported to be associated with detrimental effects to mother or
baby [27]. However, future research is necessary to understand the long-term consequences of this
calorie restriction paradigm on BPH/5 offspring, including the effects on blood pressure and renal
function. Additionally, BPH/5 mice may consume the allotted food within the pair-feeding paradigm
in a way that could result in a fasted state. The effects of intermittent fasting are most prevalent when
it occurs in the nocturnal phase, so pair-feeding took place in the morning to avoid introducing this
as a variable [28]. Finally, complement proteins are synthesized throughout the body by a variety
of cell and tissue types, including, but not limited, to liver tissue, neural tissue, immune cells, and
adipose tissue [10]. We chose to focus on reproductive WAT due to its close proximity to the developing
placenta. Additional research is required to better understand all sources of complement dysregulation
that may contribute to PE in this model.
While maternal weight loss promotes pleiotrophic positive outcomes on the dam, the mechanistic
studies herein provide new knowledge into the beneficial effects of adiposity reduction in pregnancy.
Complement, adiposity, and angiogenic associations should be further investigated to identify causation
in this model. Preliminary data in BPH/5 supports improvement in maternal and fetal adverse PE
outcomes, however, studies are ongoing to investigate the contribution of obesity on the hypertensive
phenotype in BPH/5 pregnant mothers. In summary, reduction of maternal adipose tissue during early
pregnancy could ameliorate the aggravated inflammatory profile that characterizes BPH/5 reproductive
WAT and implantation sites prior to placenta formation, which was shown to be causal in fetoplacental
development and hypertension in this model.
5. Conclusions
Maternal obesity prior to and during early pregnancy may be a therapeutic target for PE
intervention. A reduction in adipose tissue by CR holds promise for ameliorating inflammatory and
angiogenic dysregulation at the maternal–fetal interface, thereby reducing the risk of PE (Figure 4).
Unfortunately, given the systemic effects of CR, it is difficult to elucidate the precise mechanism
of action whereby reduced maternal adiposity improves pregnancy outcomes. Of note, this study
was conducted in a mouse model to begin understanding the complex PE etiology; extrapolating
interventions from animal models to humans requires more research. Future studies should inquire
into the mechanisms linking obesity, the immune system, and PE, particularly regarding identification
of the immune cell types responsible for producing complement components and contributing to the
inflammatory milieu characterizing the maternal–fetal interface during PE.
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